Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Down 51.0% in October

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 853,200 shares, a decrease of 51.0% from the September 30th total of 1,740,000 shares. Based on an average daily trading volume, of 10,730,000 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Applied DNA Sciences to a “sell” rating in a research note on Tuesday, September 17th.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently raised its position in Applied DNA Sciences stock. AMH Equity Ltd grew its position in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 540,385 shares of the technology company’s stock after buying an additional 170,385 shares during the quarter. AMH Equity Ltd owned 63.57% of Applied DNA Sciences worth $222,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.22% of the company’s stock.

Applied DNA Sciences Price Performance

NASDAQ:APDN opened at $0.31 on Friday. Applied DNA Sciences has a fifty-two week low of $0.28 and a fifty-two week high of $22.80. The firm’s fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.64. The stock has a market cap of $304,759.00, a PE ratio of -0.02 and a beta of 0.34.

Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Thursday, August 8th. The technology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.64) by $1.11. Applied DNA Sciences had a negative net margin of 214.42% and a negative return on equity of 138.41%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.95 million. During the same period in the prior year, the business posted ($4.80) earnings per share. Equities analysts anticipate that Applied DNA Sciences will post -1.8 earnings per share for the current year.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.